What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.”In the company’s words, NCT06534060 on ClinicalTrials.gov
- Tested for
- Lymphoma, T-Cell
- Main trialPhase 2
- “This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.”In the company’s words, NCT06534060 on ClinicalTrials.gov
Other drugs for Lymphoma, T-Cell
- XNW5004Evopoint Biosciences Inc. · Phase 3
- GolidocitinibDizal Pharmaceuticals · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- TR115Tarapeutics Science Inc. · Phase 3
Coming up1
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2028 | MB-105 in Patients With CD5 Positive T-cell Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026